This unique and patented formulation technology achieves 79% deposition of the fine particle fraction and 70% deposition of the expired fraction using a standard inhaler device, representing a breakthrough in inhalation therapy.

These key data represent an important step forward in confirming Aquilon Pharma’s potential in the development of formulations for dry powder inhalers.

As a result, Aquilon can now move forward with great confidence with dry powder formulations of novel and biologic treatments to be delivered by inhalation.

L’article Aquilon proves the high potential of HP-Betadex in Dry Powder formulation est apparu en premier sur Aquilon Pharma.

The panel of international experts sitting on the jury notes that “the project remains very interesting and has strong industrial potential”.

L’article Aquilon and partners cross the mid-term milestone for Aeronext est apparu en premier sur Aquilon Pharma.

Aquilon Pharmaceuticals immediately kicked off the project to add International Expertise and Experience to its different Governance layers, and started the implementation, following unanimous acceptance of the plan by the Board on December 7th.

In a first phase of this exercise, the Board of Directors approved the nomination of Dr Hassan Benameur as Board Member, replacing Mr Patrick Jeanmart who decided to step down to focus on other activities.

Dr Hassan Benameur has a PhD in Pharmaceutical and Drug Design and is Chemical Engineer Chemistry and Biochemistry. He previously held executive positions at Lonza, Pfizer and Capsugel and is Adjunct Professor at Monash University. In addition to his role at the Board, Dr Benameur will assist the executive team in Scientific Affairs and Business Development.

Aquilon Pharmaceuticals wishes to thank Patrick Jeanmart and warmly welcome Dr Hassan Benameur.

With these moves, the first phase of the Board reshuffle is completed. A second phase, including new nominations, will be announced by the end of January 2023.

L’article Board reshuffle at Aquilon Pharmaceuticals est apparu en premier sur Aquilon Pharma.

Following the successful completion of its toxicity trials, Aquilon Pharmaceuticals has now initiated clinical trials in humans. The first pharmacokinetic trial, conducted in 4 x 24 subjects, comparing the Budesonide – HP-Betadex complex with a Budesonide reference product (Pulmicort), showed results, confirming the early-stage findings.

“No side effects have been reported, in neither of the three groups of patients treated with our product or with Pulmicort” confirms Paul Maes, CEO and co-founder of Aquilon Pharma. This demonstrates the safety of our product! On top of that, the pharmacokinetics of our product are linear and similar to the reference product,” he adds.

Aquilon Pharmaceuticals tend to believe that these positive results will pave the way for a simplified registration procedure with the FDA (USA) and allow a shortened time to marketing authorization.

The US market is one of the focus markets for Aquilon Pharmaceuticals, who recently brought in some industry experts who will bring all the required expertise and experience necessary to successfully complete the registration file with the FDA in the USA.

Aquilon Pharma develops “Value Added Inhaled Medicines” by reformulating known molecules and therefore improving their effectiveness when administered by inhalation. The novel formulations, based on creating HP-Betadex complexes, provide a better pulmonary deposition of the molecule and thus a better local bioavailability.

Aquilon Pharma is a spin-off from the University of Liege, founded at the end of 2013, specializing in the improvement of existing treatments for pulmonary diseases, such as Asthma and Chronic Obstructive Pulmonary Diseases (COPD) and the co-development of novel inhaled treatments.

Chronic respiratory diseases are among the leading causes of mortality and morbidity around the world, and their prevalence continues to grow, as reported by the World Health Organization (WHO).

Thanks to the results of this first trial, Aquilon Pharmaceuticals has achieved a major step in realizing its ambition and have just taken a decisive step in their development.

X X X

(*) Aquilon Pharma ( www.aquilonpharma.be ) Aquilon Pharma has already filed 8 patents worldwide in this context. The US patent was granted in June 2018 by the USPTO (the United States Patent and Trademark Office). Aquilon Pharma currently employs around 20 people. In the medium term, the company plans to employ around fifty people.

For more information, please contact:

• Paul Maes, CEO, pmaes@aquilonpharma.com – +32(0)4/229.28.00 or +32(0)471/421.065
• Damien Thiéry, COO & CCD, dthiery@aquilonpharma.com – +32(0)496/59.04.78

L’article News Release est apparu en premier sur Aquilon Pharma.

Source: L’Echo – Full article on request.

L’article Collective representative office in Texas est apparu en premier sur Aquilon Pharma.

L’article New laboratories est apparu en premier sur Aquilon Pharma.

Concerned by the significant respiratory consequences of COVID 19 infections, both during and after the disease, Aquilon Pharma has launched its first Phase II clinical trial, using its own funds, to provide therapeutic support for Covid 19 patients admitted to hospital in acute respiratory distress.

This study, named Sirocco 1, will be conducted in collaboration with the University of Liège.

The SIROCCO 1 clinical trial is a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of Aquilon Pharma’s therapeutic innovation in the management of acute COVID-19 symptoms. The evolution of pharmacodynamic parameters, such as inflammatory and cardiac biomarkers, will also be studied during the study.

A total of 99 adult patients hospitalized with a positive SARS-CoV-2 RT-PCR test will be included in the clinical trial. Dr Julien Guiot from the University of Liège is the principal investigator. The study will be carried out at the University Hospital of Liège, with a second major hospital in the Liège region to be selected subsequently. Patients will receive either two different inhalation dosages of the treatment developed by Aquilon Pharma, or a placebo treatment for 28 days.

Paul Maes, CEO of Aquilon Pharma, comments: “The fact that we are able to carry out such a Phase II clinical trial today already demonstrates the relevance of the research and therapeutic innovation developed by Aquilon Pharma. This is an undeniable sign that the company will play an important role in the future and become a leading pharmaceutical player in the treatment of severe respiratory diseases worldwide.”

The Sirocco1 research project will have three components:

• Therapeutic evaluation of Covid 19 patients admitted directly to intensive care units.
• Therapeutic evaluation of Covid 19 patients admitted to the Respiratory Care Department.
• Therapeutic evaluation of Covid 19 patients convalescing at home.

Initial results from Sirocco1 are expected by the end of August. The overall results of the 3 parts of the study will be known during the last quarter of this year.

L’article Aquilon Pharma launches a Phase II clinical trial for Covid19 patients in the acute respiratory phase est apparu en premier sur Aquilon Pharma.

Aquilon Pharma, originally founded as a spinout from the University of Liège, Belgium, has an innovative portfolio of new formulations that significantly improves the efficacy of inhaled drugs for asthma and COPD (Chronic Pulmonary Obstructive disorder). Strongly focused on precision and quality, the company’s dry powder and nebulized formulations can also be used in developing existing non-inhaled drugs as inhalable.

Aquilon Pharma has ordered PreciseInhale®, ISAB’s high-precision aerosol R&D system, plus its Nose-Only and the unique Intratracheal Exposure Modules. The total order is worth 292 KEUR.

ISAB CEO Manoush Masarrat: “We are pleased to welcome a fellow pioneer in nextgeneration inhalation technology as new customer. We know how deeply Aquilon Pharma value precision and efficacy as key drivers for better treatment and care for patients, and we’re proud that PreciseInhale® will be playing an important role in helping them achieve that.”.

Aquilon Pharma CEO Paul MAES: “Aquilon is happy to acquire the PreciseInhale® equipment. It will be a great opportunity to work, together with highly experienced colleagues from the University, on innovative respiratory medicine research. Through this unique technology we will be able to move forward and extend the portfolio of our products in development. Aquilon intends to address all the challenges existing in the field of lung disease treatments and proposes drug products that are environmentfriendly, easy to use and which allow a better lung deposition. Aquilon will carry out three clinical studies in 2021 to finalize its research. The company is today launching a 20 MEURO fund-raising campaign to finance its pre-commercialization projects.”.

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for aerosol generation and inhalation research. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on December 18, 2020 at 0945 CET.

L’article Aquilon Pharma has signed a purchase order for ISAB’s high-precision R&D system PreciseInhale® est apparu en premier sur Aquilon Pharma.